Stock Titan Trading tools for traders and investors.

-

05:36:56 PM

Last PFE Stock Market News

PFE - Pfizer Inc.

03/04/21 10:00 AM

NYSE : PFE

Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference

Pfizer Inc. (NYSE: PFE) invites investors and the general public to listen to a webcast of a discussion with Frank D'Amelio, Chief Financial Officer, Executive Vice President, Global Supply, at the Barclays Global Healthcare Conference on Thursday, March 11, 2021 at 1:15 p.m. Eastern Standard

RHEA-AI

neutral

03/03/21 7:03 PM

NYSE : PFE

U.S. FDA Expands Approval of Pfizer's LORBRENA(R) as First-Line Treatment for ALK-Positive Metastatic Lung Cancer

The U.S. Food and Drug Administration (FDA) approved Pfizer Inc.'s (NYSE: PFE) supplemental New Drug Application (sNDA) for LORBRENA (R) (lorlatinib), expanding the indication to include first-line treatment of people with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC).

RHEA-AI

positive

03/02/21 7:00 AM

NYSE : PFE

Strata Oncology Announces the Strata PATH Trial with Pfizer as First Pharma Partner

Strata Oncology, Inc., a precision oncology company advancing molecular indications for cancer therapies, today announced the Strata P recision Indications for A pproved Th erapies, or "Strata PATH," trial. Strata PATH is a multi-drug, multi-arm,

RHEA-AI

very positive

02/26/21 6:45 AM

NYSE : PFE

European Medicines Agency Accepts Pfizer's Marketing Authorization Application for Its Investigational 20-valent Pneumococcal Conjugate Vaccine for Adults 18 Years of Age or Older

Pfizer Inc. (NYSE:PFE) today announced that the European Medicines Agency (EMA) accepted for review the Marketing Authorization Application (MAA) for its 20-valent pneumococcal conjugate vaccine (20vPnC) candidate, as submitted for the prevention of invasive disease and pneumonia caused by

RHEA-AI

neutral

02/26/21 6:30 AM

NYSE : PFE

EMA Accepts Marketing Application for Somatrogon to Treat Pediatric Patients with Growth Hormone Deficiency

Pfizer Inc. (NYSE: PFE) and OPKO Health Inc. (NASDAQ: OPK) announced today that the European Medicines Agency (EMA) has validated for review the Marketing Authorization Application (MAA) for somatrogon, a long-acting recombinant human growth hormone that is intended to be administered once-weekly

RHEA-AI

neutral

02/25/21 6:45 AM

NYSE, Nasdaq : PFE, BNTX

Pfizer and BioNTech Initiate a Study as Part of Broad Development Plan to Evaluate COVID-19 Booster and New Vaccine Variants

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced today they have begun an evaluation of the safety and immunogenicity of a third dose of the Pfizer-BioNTech COVID-19 vaccine (BNT162b2) to understand the effect of a booster on immunity against COVID-19 caused by the circulating and

RHEA-AI

negative

02/24/21 8:00 AM

NYSE : PFE

Seven Bridges Selected by Pfizer to Support Data Management Solution for Single-Cell RNA Sequencing Data

Seven Bridges, the industry-leading bioinformatics ecosystem provider, is supporting Pfizer Inc. (NYSE: PFE) in the development of a data management and collaboration solution for the biopharmaceutical company's single-cell ribonucleic acid (RNA) sequencing

RHEA-AI

neutral

02/23/21 4:30 PM

NYSE : PFE

U.S. FDA Accepts for Priority Review Pfizer's Application for TicoVac(TM) (Tick-borne Encephalitis Vaccine)

Pfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug Administration (FDA) accepted for Priority Review the company's Biologics License Application (BLA) for TicoVac(TM), its tick-borne encephalitis (TBE) vaccine for active immunization to prevent TBE in individuals 1 year of age and

RHEA-AI

neutral

02/22/21 10:00 AM

NYSE : PFE

Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference

Pfizer Inc. (NYSE: PFE) invites investors and the general public to listen to a webcast of a discussion with Angela Hwang, Group President, Pfizer Biopharmaceuticals Group, at the Cowen 41 st Annual Health Care Conference on Monday, March 1, 2021 at 3:20 p.m. Eastern Standard Time.To listen to

RHEA-AI

neutral

02/17/21 6:45 AM

NYSE : PFE

Pfizer Initiates Pivotal Phase 2 MagnetisMM-3 Trial of BCMA-CD3 Bispecific Antibody Elranatamab (PF-06863135) in Multiple Myeloma

Pfizer Inc. (NYSE:PFE) today announced that the first participant has been dosed in the registration-enabling Phase 2 MagnetisMM-3 study (NCT04649359) of elranatamab (PF-06863135), an investigational B-cell maturation antigen (BCMA) CD3-targeted bispecific antibody, in patients with

RHEA-AI

positive

1 2 3 4 5 6 7 8 Next